By: IPP Bureau
Last updated : January 30, 2026 9:30 pm
With its unique combination of AI, population-specific research, and international collaboration, BioMed X’s Barbados project represents a bold new frontier in precision medicine for diabetes and kidney disease
BioMed X, a leading global innovation hub for pharmaceuticals, has launched its first research project in direct partnership with the Government of Barbados, with backing from the European Union’s PharmaNext Programme.
The initiative, titled “AI-Enabled Therapy of Early Diabetic Kidney Disease in Barbados,” targets one of the most urgent and underexplored challenges in cardiometabolic disease: the biological variability of early diabetic kidney disease in Barbadian patients with Type 2 Diabetes.
With its unique combination of AI, population-specific research, and international collaboration, BioMed X’s Barbados project represents a bold new frontier in precision medicine for diabetes and kidney disease.
The project aims to map the molecular mechanisms behind early diabetic kidney disease using advanced AI modeling and deep molecular profiling. Researchers will combine data from Barbadian patients and healthy controls to construct a population-specific digital African twin, designed to improve patient stratification, discover novel biomarkers, and guide adaptive, data-driven therapies.
BioMed X, in collaboration with European and public partners, is inviting innovative research proposals focusing on: Molecular profiling of Barbadian Type 2 Diabetes patients with early diabetic kidney disease and matched healthy controls; Development of an AI-driven digital African twin to capture population-specific disease heterogeneity and predict disease trajectories; Identification and validation of new molecular biomarkers for personalized treatment in Barbados.
This marks a milestone for BioMed X, extending its global talent-sourcing model into direct collaboration with a national government.
“By partnering directly with the Government of Barbados and with support from the European Union, we are applying our global talent-sourcing and incubation model to a real-world public health challenge in an underrepresented population,” said Leisel Juman, CEO of BioMed X Barbados.
“This initiative creates a structured pathway from fundamental discovery to real-world impact—while equipping Barbados with the capabilities to contribute meaningfully to the global innovation landscape.”
Jonathan Reid, Minister of Innovation, Industry, Science and Technology, added: “This launch reflects our commitment to positioning science and technology at the heart of Barbados’ future. Through collaboration, talent development, and early engagement of our young people, we are laying the groundwork for an innovation ecosystem that is globally connected and capable of driving sustainable national growth.”
Fiona Ramsey, EU Ambassador to Barbados, said: “Through the PharmaNext Programme, the European Union is committed to supporting innovative research partnerships that address global health challenges while strengthening scientific capacity. This project exemplifies how European support, local leadership, and international scientific excellence can come together to deliver impactful, inclusive innovation.”